Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 2/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CA3 | P07451 | 2/20 | 0.37 |
| ▸ | CA4 | P22748 | 2/20 | 0.37 |
| ▸ | CA6 | P23280 | 2/20 | 0.37 |
| ▸ | CA5A | P35218 | 2/20 | 0.37 |
| ▸ | CA7 | P43166 | 2/20 | 0.37 |
| ▸ | CA9 | Q16790 | 2/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.37 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | LCK | P06239 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29198096 | 1.00 | CHRM2 (0.42) | CHRM2NFKB1CA12CA1CA2 | |
| SCHEMBL7523529 | 0.97 | CHRM2 (0.46) | CHRM2NFKB1CA12CA1CA2 | |
| SCHEMBL29837911 | 0.97 | CHRM2 (0.46) | CHRM2NFKB1CA12CA1CA2 | |
| SCHEMBL422343 | 0.97 | CHRM2 (0.46) | CHRM2NFKB1CA12CA1CA2 | |
| SCHEMBL9190540 | 0.97 | CHRM2 (0.46) | CHRM2NFKB1CA12CA1CA2 | |
| SCHEMBL30186917 | 0.97 | CHRM2 (0.40) | CHRM2NFKB1CA12CA1CA2 | |
| SCHEMBL11591877 | 0.92 | TSHR (0.39) | CHRM2NFKB1CA12CA1CA2 | |
| SCHEMBL1674639 | 0.92 | TSHR (0.39) | CHRM2NFKB1CA12CA1CA2 | |
| SCHEMBL352467 | 0.92 | TSHR (0.39) | CHRM2NFKB1CA12CA1CA2 | |
| SCHEMBL24227290 | 0.90 | CHRM2 (0.33) | CHRM2TSHRALDH1A1LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7790902-B2 | Isothiazole derivatives useful as anticancer agents | PFIZER, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-20080300249-A1 | tyrosine kinase inhibitors such as 5-(3,3-Dimethyl-ureido)-3-heptyloxy-isothiazole-4-carboxylic acid amide, used for treating hyperproliferative disorders in mammals; anticarcinogenic agents; antiproliferative agents | PFIZER, INC. (US) | 2008-12-04 | — | — | US | disclosed |
| US-7405218-B2 | Isothiazole derivatives useful as anticancer agents | PFIZER, INC. (US) | 2008-07-29 | — | — | US | disclosed |
| EP-0927174-B1 | NEW AMINO ALCOHOL DERIVATIVES, PROCESS FOR THE PRODUCTION THEREOF AND MEDICAMENTS AND REAGENTS CONTAINING THESE COMPOUNDS | MEDIGENE AG (DE) | 2007-12-12 | — | — | EP | disclosed |
| US-7097854-B2 | Amino alcohol derivatives, process for their production and pharmaceutical preparations and reagents containing these compounds | MEDIGENE ONCOLOGY GMBH (DE) | 2006-08-29 | — | — | US | disclosed |
| CN-1616386-A | Intermediate for preparing isothiazole derivatives | PFIZER PROD INC (US) | 2005-05-18 | — | — | CN | disclosed |
| CN-1172918-C | Isothiazole derivatives as anticancer agents | �Ʒ� | 2004-10-27 | — | — | CN | disclosed |
| EP-1084114-B1 | ISOTHIAZOLE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PROD INC (US) | 2004-09-08 | — | — | EP | disclosed |
| US-20030236266-A1 | Amino alcohol derivatives, process for their production and pharmaceutical preparations and reagents containing these compounds | ROCHE DIAGNOSTICS GMBH | 2003-12-25 | — | — | US | disclosed |
| US-20030149048-A1 | Isothiazole derivatives useful as anticancer agents | PFIZER INC. | 2003-08-07 | — | — | US | disclosed |
| WO-1999062890-A1 | ISOTHIAZOLE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PRODUCTS INC. (US) | 1999-12-09 | — | — | WO | disclosed |
| CN-1237161-A | New amino alcohol derivatives, process for production thereof and medicaments and reagents containing these compounds | ROHER DIAGNOSTIC EQUIPMENT AG (DE) | 1999-12-01 | — | — | CN | disclosed |
| EP-0773716-A4 | TREATING RED BLOOD CELL SOLUTIONS WITH ANTI-VIRAL AGENTS | CERUS CORP (US) | 1999-08-04 | — | — | EP | disclosed |
| EP-0927174-A1 | NEW AMINO ALCOHOL DERIVATIVES, PROCESS FOR THE PRODUCTION THEREOF AND MEDICAMENTS AND REAGENTS CONTAINING THESE COMPOUNDS | MediGene Oncology GmbH (DE) | 1999-07-07 | — | — | EP | disclosed |
| WO-1998011082-A1 | NEW AMINO ALCOHOL DERIVATIVES, PROCESS FOR THE PRODUCTION THEREOF AND MEDICAMENTS AND REAGENTS CONTAINING THESE COMPOUNDS | ROCHE DIAGNOSTICS GMBH (DE) | 1998-03-19 | — | — | WO | disclosed |
| EP-0773716-A1 | TREATING RED BLOOD CELL SOLUTIONS WITH ANTI-VIRAL AGENTS | Cerus Corporation (US) | 1997-05-21 | — | — | EP | disclosed |
| WO-1996039818-A1 | TREATING RED BLOOD CELL SOLUTIONS WITH ANTI-VIRAL AGENTS | CERUS CORPORATION (US) | 1996-12-19 | — | — | WO | disclosed |
| EP-0080817-B1 | A PROCESS FOR REMOVING ACID GASES USING A BASIC SALT ACTIVATED WITH A NON-STERICALLY HINDERED DIAMINO COMPOUND | EXXON RESEARCH AND ENGINEERING COMPANY (US) | 1985-07-10 | — | — | EP | disclosed |
| EP-0080817-A1 | A process for removing acid gases using a basic salt activated with a non-sterically hindered diamino compound | EXXON RESEARCH AND ENGINEERING COMPANY (US) | 1983-06-08 | — | — | EP | disclosed |
| US-4376102-A | AMINO ACID AS COSOLVENT | EXXON RESEARCH AND ENGINEERING CO. (US) | 1983-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300249-A1 | tyrosine kinase inhibitors such as 5-(3,3-Dimethyl-ureido)-3-heptyloxy-isothiazole-4-carboxylic acid amide, used for treating hyperproliferative disorders in mammals; anticarcinogenic agents; antiproliferative agents | CDKN1A, TK1, CDK1 | CHRM2 4209/4885NFKB1 825/4885CA12 4795/4885 |
| US-20030149048-A1 | Isothiazole derivatives useful as anticancer agents | TP53, MCL1, ACIN1 | CHRM2 4172/4885NFKB1 927/4885CA12 4414/4885 |
| US-20030236266-A1 | Amino alcohol derivatives, process for their production and pharmaceutical preparations and reagents containing these compounds | ADH1C, ADH1A, ADH5 | CHRM2 252/4885NFKB1 1151/4885CA12 2380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.